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ABSTRACT 
 
 
Recent studies have shown that many cancerous tumors contain “cancer stem 
cells” (CSCs) that may be responsible for the self-renewing properties of the tumor. A 
common cancer treatment, chemotherapy, targets rapidly dividing cells, but could 
possibly be ignoring the more slowly dividing CSCs.  The CSCs were characterized in a 
variety of tumors using immunofluorescence to identify stem cell markers after treatment 
with a common chemotherapy, Doxorubicin. The resulting data show statistically 
significant evidence for the presence of stem cell markers in cells left behind after 
chemotherapy treatment. 
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BACKGROUND 
Cancer Stem Cell Theory 
Cell turnover is a tightly regulated process in human tissues. Each tissue in the 
human body is comprised of many highly specialized cells with life spans of a few days 
or even hours.  Many cells are constantly being replenished with new, healthy, yet short-
lived cells, while other special cells in the tissue (stem cells) are unusually long-lived, are 
less specialized, and are fewer in number than the short-lived population. One hypothesis 
about the derivation of the specialized cells is that the stem cells control the cell turnover 
process, which helps to renovate human tissues (Dalerba et al., 2007.) 
Stem cells have three main properties: differentiation, self-renewal, and 
homeostatic control. Differentiation allows a stem cell to become a highly specialized, 
short-lived, tissue-specific cell. This property allows stem cells to continuously replenish 
tissues with short-lived specialized cell populations. Stem cells also have the ability to 
divide and give rise to genetically identical cells with similar levels of differentiation, 
self-renewal, and homeostatic control properties – essentially, they keep the stem cell 
population continuous. When genetic constraints and environmental stimuli are present, 
stem cells are able to evenly regulate the balance between self-renewal and differentiation 
(Dalerba et al., 2007). 
Like normal tissues, tumors also contain long-lived cells similar to the stem cells 
found in normal tissue. These “Cancer Stem Cells” (CSCs) are thought to be diseased 
stem cells that give tumors their heterogeneous cell populations (Clarke & Fuller, 2006).  
It is also thought that tumors arise from a single target cell that undergoes multiple 
genetic mutations over a period of years (Fearon & Volgelstein, 1990). Since the target 
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mutations take time, the only cells able to accumulate these mutations would be stem 
cells (Dalerba et al., 2007). 
According to the CSC model, tumors are comprised of a heterogeneous 
population of cells with different differentiation properties (Dalerba et al., 2007). CSCs, 
when transplanted into mice, are able to reconstitute the original tumor, including the 
phenotypic heterogeneity of the parent tumor (Gu et al., 2007). This was demonstrated by 
the induction of glioblastoma tumors in vivo using chemotherapeutic drug-resistant 
cancer stem-like cells isolated from brain cancer tissue (Kang & Kang, 2003). 
In order to define the existence of CSCs, Cho, Clarke and Dalerba explain three 
observations seen in CSC populations. First, stem cells isolated from a tumor regenerate 
when transplanted into mice. Only a small subpopulation of cells from the tumor has this 
potential. Second, a specific collection of surface markers (cell determinants, CD) 
classify tumorigenic cancer cells. Third, CSCs produce tumors of a mixed population of 
cells that are a complete regeneration of the parent tumor (Dalerba, et al., 2007). 
Evidence for the Theory 
The first experimental proof that showed cancer derived cells mimicking a normal 
stem cell hierarchy was seen in human neoplastic disease.  NOD-SCID mice injected 
with a CD34+/CD38neg subpopulation of human leukemia tumor displayed the original 
tumor  (Dalerba, et al., 2007).  
In addition, in human colon cancer cells it has been shown that CD133+ (a 
possible CSC marker) cells - unlike CD133- cells - are able to initiate tumor growth when 
transplanted into immunodeficient NOD/SCID mice (Ricci-Vitiani et al, 1998; O'Brien, 
et al., 2007). These human colon cancer-initiating cells (CC-ICs) were discovered to 
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reestablish tumor heterogeneity by differentiating and also regenerating themselves upon 
several serial transplantations (O'Brien et al., 2007). 
In another study at Vanderbilt University, a fully reconstituted human prostate 
cancer tumor was recovered through serial transplantation experiments in vivo. The cell 
lines recovered in the experiment positively expressed CD44 and Nestin (early progenitor 
markers) (Gu et al., 2007). 
In breast tissue, it has been shown that a subpopulation of most human breast 
cancer tumor clones, defined as CD44+/CD24-/low, can sustain tumor growth in 
NOD/SCID mice. These cells represent only 11-35% of the total cancer cells, yet can 
completely regenerate the phenotypic heterogeneity of the parent tumor (Raouf et al., 
2005).    
Chemoresistance 
 
Several studies have also demonstrated that cancer stem cells have high levels of 
drug resistance, thus they can survive after a tumor has been treated with chemotherapy. 
These findings have raised concerns about current drug treatments for tumors, since the 
drug resistant properties of CSCs could allow them to be selected for during 
chemotherapy treatment.  If CSCs in fact are drug resistant, then chemotherapy 
treatments essentially are selecting for tumorigenic stem cells that will eventually give 
rise to new tumors.  A study by Levina et al. (2008) examined lung cancer stem cells 
selected with various chemotherapy drugs.  The study found that the cells surviving after 
treatment with drugs such as doxorubicin, cisplatin, or etoposide expressed the stem cell 
markers CD133, CD117, SSEA-3, TRA1-81, Oct-4, and β-catenin.  The surviving cells 
also exhibited the loss of differentiation markers such as cytokeratins 8/18.  In addition, 
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the drug-surviving cells were able to create tumor spheres in vitro and created metastatic 
tumors when implanted into SCID mice (Levina et al., 2008).  All of the results of this 
particular experiment provide strong evidence that cells that survive chemotherapy 
treatments are in fact stem cells, and that these stem cells indeed have the capability of 
forming new malignant tumors.   
Doxorubicin 
Chemotherapy is a widely used cancer treatment that involves the use of a single 
or a combination of anti-cancer drugs. Most chemotherapy drugs target cells that are 
rapidly dividing (a characteristic of cancer cells); however, several normal cells of the 
body, such as hair cells and blood cells, also divide rapidly. Since all chemotherapy drugs 
affect both cancer and normal cells, the goal is to design drugs that affect cancer cells 
more severely than normal cells (Merck, p.1043-1044).  
An effective chemotherapy drug will interrupt a key function of a cancer cell, thus 
killing or severely impairing the survival of the cell. There are several main classes of 
chemotherapy drugs: alkylating agents, anti-metabolites, anti-tumor antibiotics, 
topoisomerase inhibitors, mitotic inhibitors, and corticosteroids.  
The drug used in this project was Doxorubicin, a drug classified most often as an 
anthracycline, but also as a topoisomerase inhibiter and alkylating agent.   According to 
the American Cancer Society (2008), anthracyclines are a broad class of anti-tumor 
antibiotics that interfere with enzymes during DNA replication. More specifically, 
Doxorubicin interferes with topoisomerases, which are enzymes involved in the 
separation of DNA strands during replication. Finally, Doxorubicin can be classified as 
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an alkylating drug, one that directly damages DNA in a nonphase-specific manner 
(American Cancer Society, 2008).  
As mentioned above, chemotherapy targets rapidly dividing cells, possibly 
leaving behind slower dividing cancer stem cells that have the ability to reconstitute the 
entire tumor. DOX was used in the current MQP to test the hypothesis that recurring 
tumors are caused by the presence of tumor stem cells left behind after chemotherapy 
treatments.   
Discovery  
The discovery of Doxorubicin was first published by scientists in Milano, in 1969 
under the name Adriamycin. This new cancer biotic, as it was called at the time, was the 
14-hydroxy derivative of daunomycin.  Daunomycin, isolated from the bacteria 
Streptomyces peucetuius, was shown to successfully treat acute leukemia in children. In 
order to produce other successful cancer treatments, Arcamone et al. thought it would be 
worthwhile to create a derivative of daunomycin by mutagenizing the original strain S. 
peucetius (Arcamone, et al., 1969).  
After treating the parent culture with the mutagen N-nitroso-N-methyl urethane, 
the surviving colonies were termed S. peucetius var. caesius. An isolated metabolite 
produced by this mutagenic strain, adriamycin, was a new compound similar to the 
structure of daunomycin. Initial chemotherapeutic studies of the new drug indicated that 
there was a “marked retardation” of cancers more favorable than the original drug 
daunomycin (Arcamone, et al., 1969). 
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Current Usages 
Doxorubicin inhibits normal cell function by interfering with DNA replication in 
three ways: via enzyme interference, direct DNA damage, and the formation of reactive 
oxidative species. The drug prevents protein synthesis and DNA replication by 
intercalating between DNA base pairs, thus damaging the helix and preventing 
replication. Also during DNA replication, Doxorubicin inhibits Topoisomerase II by 
specifically inhibiting the ligation properties of the enzyme after the induced double-
strand breakage, therefore resulting in the formation of a cleavable DNA-enzyme 
complex (Cutts et al., 2005).  Finally, Doxorubicin produces oxygen free radicals, which 
result in cytoxicity (National Cancer Institute, 2009). 
Since Doxorubicin is able to be used in treatment against a wide variety of 
tumors, it is one of the most valuable agents in clinical use (Cutts et al., 2005). The major 
downside of the drug is that it has been shown to induce cardiotoxicity (DeVita, et al., 
2001), which has sparked major efforts to develop less cardiotoxic and more effective 
derivatives. The research involved in finding and using these derivatives has allowed 
doxorubicin to become one of the most widely used of all clinical anti-cancer drugs 
(Weiss, 1992). 
Dangerous Effects of DOX on the Body 
One of the most concerning problems with doxorubicin is that it has been seen as 
highly cardiotoxic. This cardiotoxicity limits the vast utility of the drug, and has fueled 
research into alterations/modifications that could make the drug safer for human 
treatment.  In a review of the dangerous side effects of this popular chemotherapy 
treatment, Saltiel and McGuire showed that the prevalence of cardiomyopathy is 
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anywhere between 1.7-6.8% which can appear within a minimum of one week following 
the final dose of the drug.  Risk factors include: age, dosing regimen, total dose, 
mediastinal irradiation, and others (Saltiel & McGuire, 1983).  
One way doxorubicin may induce cardiomyopathy is typical of anthracycline 
drugs (Saltiel & McGuire, 1983): the production of superoxides caused by the initial 
reduction of doxorubicin to a semiquinone radical (Doroshow et al., 1979), followed by 
the reduction of NADPH to form the superoxide  (Myers et al., 1977). The formation of 
these superoxide radicals cause a chain reaction (Saltiel & McGuire, 1983) which 
ultimately produces malondialdehyde, levels of which have been measured in rats and in 
human plasma (Myers et al., 1977). Saltiel and McGuire also suggest that doxorubicin 
degrades glutathione, which in reduced form seems to protect the heart from the effects 
of doxorubicin (Saltiel & McGuire, 1983). 
To combat the possible lethal effects of this anthracycline, Saltiel and McGuire 
argue that vitamin E, when use as a pre-treatment, can “reduce the incidence of typical 
cardiac lesions and of cardiomyopathy (Saltiel & McGuire, 1983).” Known as an agent 
against free radicals in the body, vitamin E (in large doses) was shown to prolong the life 
of rabbits treated with doxorubicin (Van Vleet & Ferrans, 1990).  
Also discussed was the inhibition of coenzyme Q10 by doxorubicin. Like the 
studies with vitamin E, treatment with coenzyme Q10 has been shown to reduce the 
interference of doxorubicin with oxidative metabolism in the heart (Saltiel & McGuire, 
1983).   
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Combination Therapy 
Generally, in the United States, cancer patients are treated with a combination of 
chemotherapy drugs, in order to achieve the highest success rate.  In gastric cancers, a 
combination therapy that includes doxorubicin increases survival rate significantly 
(Wagner et al., 2006). 
In the treatment of hepatocellular carcinoma (HCC) that retains the 
asialoglycoproten receptor (ASGP-R, a surface receptor), doxorubicin has been largely 
ineffective when administered systemically due to its high toxicity to surrounding cells. 
To make doxorubicin more effective and safe, the drug can be coupled with 
macromolecules that bind to the ASGP –R so it can be targeted toward the cancer cells 
and avoid other tissues surrounding the liver. In a preclinical study, when coupled with 
lactosaminated human albumin, which contains a clinically safe glycoprotein that is 
internalized by the ASGP-Rs of HCC cells, it was shown that the conjugate was 
effectively targeted in the HCC tumor with “increased anticancer efficacy and tolerability 
(Fiume et al., 2008).” 
However, in some studies the combination of doxorubicin and drugs such as 
cyclophosphamide, mitomycin, and megestrol acetate, have increased the patients chance 
of cardiomyopathy (Saltiel & McGuire, 1983). 
Lyle Lab Interests 
 Past experiments in the Lyle laboratory have focused on identifying 
characteristics of stem cells that could allow them to give rise to tumors.  Several 
mutations in stem cells have been identified and are currently being studied by the Lyle 
lab.  A past project in the Lab identified keratin-15 as an epithelial stem cell marker (Lyle 
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et al., 1998).  The same study also identified skin stem cells as residing in the “bulge” 
area of the hair follicle, which give rise to several skin components such as the epidermis, 
hair follicle, and sebaceous glands (Lyle et al, 1998).  These findings have driven further 
research to identify mutations and mechanisms that could cause stem cells to produce 
skin tumors. 
LEF/TCF Mutations 
 Current experiments in the Lyle lab aim to understand the mutations in stem cells 
that can cause tumor formation.  In particular, the lab is focusing on LEF/TCF 
transcription factors, which normally function to maintain cellular skin homeostasis.  One 
third of human sebaceous tumors have mutations in the LEF-1 gene, a significant effect 
of LEF mutations in tumor incidences (Takeda et al., 2006).    LEF/TCF is a part of the 
Wnt/β-catenin/LEF/TCF pathway, which causes differentiation of skin stem cells into 
epidermis, hair follicles, and sebaceous glands.  Mutations in LEF/TCF may therefore 
cause dysregulation of these stem cells, giving rise to sebaceous and other epithelial 
tumors.  The role of LEF/TCF signaling in both normal and abnormal skin cell 
differentiation is shown in Figure 1.   
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Figure 1: The Role of LEF/TCF in Skin Cell Differentiation and 
Tumorigenesis. (A) Normal differentiation of multi-potent stem cells into 
epidermis, sebaceous, and hair follicle cells under LEF/TCF signaling.  (B) 
Hypothesized mechanism of tumorigenesis due to mutations in LEF/TCF.   
 
Muir-Torre Syndrome  
 Muir-Torre syndrome is a condition in which patients have multiple skin tumors 
on the face such as sebaceous carcinomas, usually in conjunction with other internal 
cancers, especially colon cancer (Cohen et al., 1991; 1995).  Most of these patients also 
show defects in the MLH1 and MLH2 DNA mismatch repair genes (Lyle grant, 2004).  
As previously mentioned, mismatch repair errors in LEF-1 occur in one third of 
sebaceous tumors.  DNA mismatch repair has also been linked with microsatellite 
instability, which is thought to be a cause of TCF-4 mutations (Fukushima et al, 2001).  
All of these factors therefore suggest that Muir-Torre syndrome patients could possess 
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abnormal LEF/TCF signaling pathways, making them good candidates for research on 
cancer stem cells in the Lyle lab. 
Midbody Retention 
 Previous experiments in the Lyle lab have also suggested that midbodies, or 
remnants of cell division, are retained in stem cells but are degraded in normally 
differentiated cells.  Midbodies form in the cleavage furrow during telophase, to aid in 
the splitting of the cell during cytokinesis.  When the cell divides, the midbody must be 
retained within one of the two daughter cells.   Cells present within adult stem cell niches 
appear to have more than one midbody, suggesting that stem cells accumulate them 
during a symmetric cell division (Lyle & Doxsey labs, unpublished).  When comparing 
normal cells to cancer cells, it was found that a high percentage of cancer cells contained 
greater than one midbody, while almost none of the normal cells contained multiple 
midbodies.  Lastly, colocalization assays showed that MKLP-1 and LAMP2 (a lysosome 
stain) existed in the same area in normal cells (Lyle & Doxsey labs, unpublished).  This 
information strongly suggests that normal cells have a mechanism for degrading 
midbodies, while stem cells retain midbodies, making them a useful stem cell marker.   
 
Immunofluorescence and Chosen Stem Cell Markers 
 Immunofluorescence is a microscopy staining technique used to identify the 
presence of antigens in cells using antibodies to the molecules of interest, tagged with 
fluorescent dye.  Cells containing antigens of interest are incubated with a primary 
antibody, and then are incubated with a secondary antibody containing a fluorescent dye.  
The stained cells and antigens are then observed using a fluorescence microscope.  In this 
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MQP, the following stem cell markers were stained and observed using immuno-
fluorescence. 
MKLP-1 
 Mitotic kinase-like protein-1 (MKLP-1) is encoded by the KIF23 gene, located on 
chromosome 15.  MKLP-1 is a motor protein involved in mitosis of mammalian cells, 
and is specifically involved in cytokinesis.  During mitosis, MKLP-1 is found in the 
midbody of the cell, which forms in the cleavage furrow during telophase (Zhu, 2005).   
After cytokinesis, MKLP-1 is left in the midbody which is left behind in one cell’s 
cytoplasm.  As mentioned before, previous experimental data has suggested that stem 
cells retain their midbodies after division, while differentiated cells do not (Lyle and 
Doxsey, unpublished).  Figure 2 below is an example of a midbody in a primary breast 
tumor cell.  
 
Figure 2: Example of a Midbody in Primary Breast Tumor 
Cell (60x).  MKLP-1 is stained in green (midbody) (diagram 
center), and CD44 is stained in red. 
 Keratin-15 
 Keratins contribute to the structure and strength of the cytoskeleton of epithelial 
cells.  Keratin-15 (K15) is an “acidic” keratin, and part of the type I keratin family.  K15 
works in conjunction with K5, its “basic” type II keratin counterpart, to create a keratin 
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filament network within epithelial cells (Radoja, 2004).  Many basal cell carcinomas 
express K15, which suggests that epithelial tumors arise from stem cells (Lyle et al, 1998; 
Jih et al., 1999). 
CD133 
 CD133 is a cell surface glycoprotein with five transmembrane domains.   It is 
usually found on neuroepithelial stem cells and is generally associated with brain tumors 
(Miki, 2007).  It has also been identified in cancer stem cells of many other tissues, 
including prostate cancer (Miki, 2007) and colon cancer (Chu, 2009).  CD133+ colon 
cells have been shown to be highly proliferative and tumorigenic when injected into 
immunodeficient mice (Ricci-Vitiani, 2007). 
CD44 
 CD44 is a cell adhesion molecule involved in cell signaling functions.  It is 
usually found in the basal cells of both normal and tumoric prostate tissue.  Some studies 
suggest that CD44+ prostate cancer cells are more tumorigenic and metastatic than 
CD44- cells (Patrawala, 2006).  CD44 has also been indicated as a colon cancer stem cell 
marker in several studies (Chu, 2009).   
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PROJECT PURPOSE 
  
As discussed in the background, malignant tumors often recur after treatment with 
chemotherapy.  This is thought to be because current chemotherapy treatments target 
rapidly dividing cells, leaving behind the more slowly dividing cancer stem cells that 
could eventually give rise to an entire new tumor.  The hypothesis being tested by this 
MQP is that cancer stem cells remain in a tumor cell population after treatment with 
chemotherapy.  Normal and abnormal (cancer) cells from several types of human tissue 
will be treated with the common chemotherapy drug doxorubicin (Dox), which will kill 
rapidly dividing cells, as occurs in normal chemotherapy treatments.  Immuno-
fluorescence staining and microscopy will then be used to determine the amounts of 
various stem cell markers remaining in the human tumor cells, and statistical analysis will 
be done to compare stem cell marker presence in normal and abnormal cell lines.  We 
hypothesize that there will be a higher percentage of cells staining positive for stem cell 
markers in tumor cell lines than in normal cell lines, and that the percentage of positive 
staining will increase after treatment with doxorubicin. 
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METHODOLOGY 
 
Cell Culture 
 
Culture Splitting 
 
All the cell lines used in this MQP were generously given by colleagues in the 
Cancer Biology department at UMASS Medical School. These cell lines were: MDA231, 
PC3, NPrEC, SEBE5E7, Tumor 1C, Clone A, Clone J, HCT116 +/+, and HCT116 -/-.  
 The MDA231 cell line was purchased originally from ATCC (#HTB-26). It is a 
female human breast cell line that expresses the WNT7B oncogene and was isolated from 
an adenocarcinoma. The cells also express epidermal growth factor (EFG) and 
transforming growth factor alpha (TGF alpha).  
 The PC3 cell line was also purchased from ATCC (#CRL-1435) and is a prostate 
grade IV adenocarcenoma. It is a tumorigenic prostate cell line obtained from a 62-year 
old male.  The cells express the antigens HLA, A1, and A9. Normal prostate epithelial 
cell line (NPrEC) was used as the normal prostate cell line. This immortalized normal 
human cell line was purchased from an unknown source.  
 The normal sebaceous cell line (SEBE6E7) was immortalized from a human 
sebaceous gland from an unknown source. The tumor sebaceous cell lines were 
genetically engineered in the Lyle Lab at UMASS Medical School. Tumor 1C was an 
immortalized sebaceous tumor cell line. The Clone A cell line was a selected clone from 
Tumor 1C with very low K15 expression levels. Clone J was also a selected clone from 
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Tumor 1C that was transfected by a K15 promoter regulated GFP construct. This cell line 
expresses high K15 levels when cultured with J2 conditioned media. 
 Finally, the HCT116 cell lines were used for human colon tumor lines. This line 
was derived from a colon adenocarcinoma from colon epithelial cells. The HCT116 -/- 
cell line has an isogenic deletion of the p53 loci using retrovile insertion. HCT116 +/+ is 
the p53 wild type. 
Culture Splitting 
 All cell lines were split using the same procedures, in either 10cm or 6-well 
Cronin dishes. The cells were washed with PBS, and 1-2mL of Trypsin 1x with Versene 
was used to dislodge the adhered cells from the bottom of the plate. Finally, the cells 
were spun at 200G (1000 RPM) for 6 minutes, then re-plated at the desired dilution either 
on the same plate or a new plate of the correct size.  
Trypsin Stock 
 10x stock Trypsin was diluted 1:5 with Hanks Balance Salt Solution to give 2x 
Trypsin. Stock Versene was mixed 1:1 with the Trypsin to give the final working solution 
of Trypsin 1x with Versene. 
Freezing Cells 
 To freeze cells that were no longer needed in active culture, the split procedure 
(above) was used until the spin down step. After spinning, cells were re-suspended in 
1mL media. Freezing Media (20% DMSO and 80% FBS) was used 1:1 with the cell 
suspension (1mL freezing media, 1mL cell suspension), and the mixture was placed in a 
2mL vial. The vial was placed in a freezing box in the -90°C freezer. 
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Cell Thawing 
 When not in culture, cells were stored in a -90°C freezer. To thaw, cells were 
placed in a 37°C water bath for several seconds until fully thawed. 10-15mL of cell 
media was placed in a 15mL conical tube while cells were thawing. Newly thawed cells 
were gently added to the cell media 50µL at a time, until the vial was fully transferred. 
The new cell suspension was spun at 200G for 6 minutes, then plated on either a 10cm or 
a 6-well Cronin plate. 
Culture Media 
 The cell lines for each tissue used different media (summarized in Table I) for 
optimal growing conditions. The procedures for making each media are explained below. 
All media was stored in a light-blocking box in a 4°C refrigerator, and thawed in a 37°C 
water bath before use. 
Breast Cell Line (MDA231) 
 The MDA231 cell line was cultured in stock DMEM (Dulbecco's Modified Eagle 
Medium) with 1% Penn/Strep and 10% FBS. 
Prostate Cell Lines (PC3 & NPrEC) 
 The prostate cell lines were cultured using Serum Free Media (SFM). A stock 
500mL Defined K SFM bottle of media was used along with 1% Penn/Strep and 1 vial of 
supplement (Keratinocyte-SFM). 
Sebaceous Cell Lines (Tumor 1C and SEBE6E7) 
 The Sebaceous cell lines were cultured in Kupffer cell medium + EGF Media 
with J2 Cell byproducts.  500 µL EGF was added to the stock 500mL bottle of KCM 
along with 1% Penn/Strep and 10% Fetal Bovine Serum (FBS) and J2 cell byproducts. 
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Colon Cell Lines (HCT116 +/+ and HCT116 -/-) 
 Both colon cell lines were cultured in DMEM with 1% Penn/Strep and 10% FBS.  
Table 1: Summary of Culture Media Used for Each Cell Line. 
Cell Line Media Used Additives 
MDA231 DMEM 1% Penn/Strep, 10% FBS 
PC3, NPrEC Defined K SFM 1% Penn/Strep 
Tumor 1C, SEBE6E7, Clone 
A, Clone J 
KCM J2 Conditioned Media EGF, 1% Penn/Strep, 10% 
FBS, J2 Cell  
HCT116 +/+, HCT116 -/- DMEM 1% Penn/Strep, 10% FBS 
 
Treatment with Doxorubicin 
 10 mg of Doxorubicin HCl was ordered from Sigma-Aldrich (catalog number 
D1515). The powder was solublized in DMSO to form a 10 mM stock solution and 
divided into 70 µL aliquots stored at -20oC in a light-blocking box.  The working 
concentration of Doxorubicin, used for the kill curves and for treatment, was a 1:10 
dilution with PBS of the 10 mM stock solution. 
 All cell lines in this experiment were treated with Doxorubicin and controlled 
with PBS at specific doses.  A “kill curve” was used for each cell line to determine which 
dose of Doxorubicin would be effective in eliminating 95% of the cell’s population. The 
determination used a visual qualitative estimation of the percentage of cells left.  
Once the appropriate dosage was determined, the cells were plated in a 6-well dish with 
the top 3 wells designated for the treatment with Doxorubicin, and the bottom 3 for the 
control with PBS. 2-3 glass cover slips were placed in 4 of the 6 wells. One well for both 
the treatment and the control were designated for the viability count, therefore were free 
of cover slips.  
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 The cells were treated every 2-3 days until 95% of the treated cells were 
eliminated. An immunofluorescent (IF) stain was completed on both the treatment and 
the control cover slips, with antibodies (Ab) specific for each of the stem cell markers.  
 
Kill Curves 
 As previously mentioned, a kill curve was used to determine the correct dosage of 
Doxorubicin needed to eliminate 95% of the cell’s population. One stock solution of a 
1:10 Doxorubicin:PBS mixture was created, then varying amounts of that dilution were 
used to establish the kill curve.  There were 6 established concentrations used in the kill 
curve: 1/750, 1/1,000, 1/2,500, 1/5,000, 1/7,500, and 1/10,000. The wells were set up 
with the concentrations as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In order to generate the concentrations in each well, varying amounts of the 1:10 
diluted Doxorubin were added to each well (Table 2). An example calculation of how to 
determine the amount is shown below with the 1/750 used.   1/750 = 1/750 of the stock 
2 1 
4 5 
3 
6 
1/750 1/1000 1/2500 
1/5000 1/7500 1/10000 
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10 mM Doxorubicin; Diluted 1:10 with PBS = [(1/750)/10] = 1/75; 2500 µL total volume 
of well, therefore: 2500/75 = 33.3µL 1:10 Doxorubicin. 
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Table 2: Kill Curve Concentrations. 
These values were used in determining optimal concentration  
of 1:10 stock to use for treatements. 
 
Well # Concentration 1:10 Doxorubicin  
or PBS added (µL) 
1 1/750 33 
2 1/1000 25 
3 1/2500 10 
4 1/5000 5 
5 1/7500 3 
6 1/10,000 2.5 
 
 Each cell line was plated on a 6-well plate until 80% confluent. Once confluent, 
the cells were treated with 1:10 Doxorubicin in the specified concentrations above. Once 
one of the wells achieved 95% elimination of cells, that concentration was indicated as 
the optimum concentration for that cell line, shown in Table 3. 
 
Table 3: Concentrations of 1:10 Doxorubicin Chosen 
From Kill Curves to be Used for Cell Line Treatment. 
Cell Line Concentration Amount 1:10 Doxorubicin 
(µL) 
MDA231 1/1000 25 
PC3 1/750 33 
NPrEC 1/5000 5 
SEBE6E7 Between 1/750 and 1/1000 30 
Tumor 1C 1/10,000 2.5 
Clone A 1/10,000 2.5 
Clone J 1/10,000 2.5 
HCT116 +/+ 1/750 33 
HCT116 -/- Between 1/1000 and 1/2500 14 
 
Doxorubicin Treatments 
 Each cell line was treated with Doxorubicin until 95% of the cell population was 
eliminated.  Table 4 shows the amount of time each cell line was treated for.  Additional 
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1:10 Doxorubicin was added to the treatment wells approximately every 2 days during 
the course of treatment. 
Table 4: Treatment Duration for Each Cell Line. 
Cell Line Number of Days of Treatment Amount 1:10 Doxorubicin Added (µL) 
MDA231 5 25 
NPrEC 7 5 
PC3 7 33 
SEBE6E7 3 30 
Tumor 1C 4 2.5 
Clone A 3 2.5 
Clone J 3 2.5 
HCT116 +/+ 6 33 
HCT116 -/- 3 14 
 
 For two of the cell lines (HCT116 -/- and SEBE6E7) an amount of 1:10 
Doxorubicin was used that was in between the tested concentrations. This was 
determined because the upper and lower concentrations were too effective or too 
ineffective, respectively; therefore, an in between amount was used.  
 In regards to the number of days each cell line was treated, they were retreated 
with the same amount of both Doxorubicin and PBS every 2 days during the week, and 
not during the week. The schedule was planned in a way that treatments mostly began on 
Friday, and were either fixed or retreated on Monday, and every 2 days after that until 
they were ready to be fixed.  
Fixing Coverslips 
 In order to fix cells to their coverslips after experimentation, all of the media was 
vacuumed off and the slips rinsed once with PBS.  The glass coverslips were then placed 
in a glass dish for fixing with either acetone or methanol.  All glass coverslips were fixed 
with acetone for 30 seconds, and plastic slips with methanol for 5 minutes.  When fixing 
time was up the fixing chemical was removed, and the slips rinsed again with PBS.  
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Fixed coverslips were stored in a six well plate with the edges sealed with parafilm in the 
2-8o C refrigerator. 
 
Immunofluorescence 
Staining 
 Immunofluorescence staining was performed so that treated cells could be 
examined for the presence of stem cell markers using fluorescence microscopy.  In 
preparation for staining, all coverslips were rinsed once with PBST (0.1% Triton-X 100) 
and then blocked with a 5% goat serum diluted in PBST for one hour.  The slips were 
then washed once more with PBST before application of primary antibody.  Slips were 
incubated with primary antibody either for 2 hours at room temperature, or overnight in 
the 4o C refrigerator.  After incubation with primary antibody, the slips were washed 4-5 
times with PBS for 3 minutes per wash.  Slips were then incubated with secondary 
antibody for 1-2 hours in the dark at room temperature, and rinsed again 4-5 times with 
PBS.  The coverslips were finally blotted dry and carefully mounted with Vectashield 
containing DAPI stain, the edges of the slide sealed, and stored in a light blocking paper 
slide folder in the 2-8o C refrigerator.  Table 5 shows the different stains performed for 
each antibody and the dilutions used for the primary and secondary antibodies. 
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Table 5: Immunofluorescent Stains Used for Each  
Cell Line Including Antibody Dilutions 
Cell Line Primary Antibody 
Primary 
Antibody 
Dilution 
Secondary 
Antibody 
Secondary 
Antibody 
Dilution 
MDA231 
Mouse CD44 1:100 Mouse Rhodamine 1:100 
Rabbit 
MKLP-1 1:1000 Rabbit FITC 1:100 
PC3 and NPrEC 
(CD133/MKLP-
1) 
Rabbit CD133 1:25 Rabbit Texas Red 1:300 
Goat 
RACGAP1 1:1000 Goat FITC 1:100 
PC3 and NPrEC 
(K15/MKLP-1) 
Mouse K15 1:100 Mouse Rhodamine 1:100 
Rabbit 
MKLP-1 1:500 Rabbit FITC 1:100 
PC3 and NPrEC 
(CD44/MKLP-
1) 
Mouse CD44 1:100 Mouse Rhodamine 1:100 
Rabbit 
MKLP-1 1:1000 Rabbit FITC 1:100 
SebE6E7, 
Tumor 1C, 
Clone A, Clone 
J 
Mouse K15 1:100 Mouse Rhodamine 1:100 
Rabbit FITC 1:500 Rabbit FITC 1:100 
HCT116+/+, 
HCT116-/- 
Rabbit CD133 1:25 Rabbit Texas Red 1:300 
Goat 
RACGAP1 1:1000 Goat FITC 1:100 
 
Microscopy 
 Once staining was complete, the stem cell marker staining for each cell line was 
examined using the fluorescence microscope.  For each slide, photos were taken of at 
least six randomized fields of view on the slide to get a representative depiction of the 
slide’s cell population. Magnification was used at either 20x or 40x, depending the size of 
the cells in the field (for ease of counting). The photos of each cell line and treatment 
 29
type were then merged using Adobe Photoshop to create a composite image of the DAPI 
stain and the red or green stains performed. 
Statistical Analysis 
Counting Cells 
 After the images were merged in Photoshop, the positive staining of each cell type 
was quantified.  First the total number of cells for each slide was counted by looking at 
the DAPI nuclear staining in each image.  Then, the number of cells staining positive for 
the variety of stem cell markers were counted.  For the MKLP-1 stain, both the number of 
cells staining positive for MKLP-1 with one midbody, and the number of cells with more 
than one midbody were counted. 
Statistics 
 A standard t-test using a 5% significance level and a one-tailed P-value was used 
for statistical analysis in these experiments.  Microsoft Excel was used to analyze all of 
the data collected from counting.  Percentages of positive staining out of the total number 
of cells for each field photo were calculated for each cell line.  The resulting percentages 
were then used to perform the t-test for the cells treated with Doxorubicin and the control 
cells for each cell line.  Statistical analysis was done in two ways; first, the  difference in 
stem cell marker levels in treated and untreated cells of a cell line were analyzed and 
second, the difference between stem cell marker levels in normal tissue were compared to 
tumoric tissue. 
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RESULTS 
 
 
 As mentioned above, the purpose of this MQP was to determine whether there is a 
population of cancer stem cells leftover following chemotherapy treatment that could be 
responsible for the genesis of a new tumor.  Immunofluorescence was used to look for 
known stem cell markers in the different cell lines tested.  Cells treated with Dox and 
untreated control cells were fluorescently stained and counted.  Statistical analysis was 
done to examine the differences in staining for stem cell markers between Dox treated 
and untreated cells, as well as between normal and tumor tissue.   
Immunofluorescence 
 
In this MQP, immunofluorescence was used to quantify the amount of positive 
CSC markers present with or without treatment with Doxorubicin in each of the cell 
lines. The data shown below supports the hypothesis that there was an increased number 
of CSC markers present in cells after treatment with Doxorubicin. All quantitative data 
can be found in the Appendix. 
The data below are grouped by cell line – MDA231, PC3, NPrEC, SEBE6E7, 
Tumor 1C, Clone J, and HCT116-/-.  Each cell line used one or more of the following 
stem cell markers: K15, MKLP-1, CD44, or CD133.  Each stain for each line was 
photographed separately at 20x magnification then merged to show all stains together. 
Photos of each cell line were taken in six randomly selected fields in order to capture the 
appropriate collection of stained cells.  
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To quantify the number of cells that tested positive for CSC markers, the cells in 
each photo were counted (using Adobe Photoshop) for evidence to support or not support 
the hypothesis. Tables were generated to show the quantitative data collected.  
MDA231 cells were treated with Doxorubicin and PBS (as a control) and the IF 
was performed using the appropriate antibodies for MKLP-1 and CD44, known stem cell 
markers (Figure 3).  Of the cells that were photographed, 18% of the treated cells and 
about 3% of untreated cells stained positive for MKLP-1 (one midbody).  None of the 
MDA231 cells stained positive for more than on midbody.  95% of the treated cells and 
4.4% untreated cells stained positive for CD44. 
 
Figure 3:  Photos of MDA231 Cells.  Cells were treated (left panel) or  
untreated (right panel) with doxorubicin and stained for stem cell markers 
MKLP-1 and CD44.  Shown at 20x. 
 
 Six random fields were photographed for PC3 co-stained with either MKLP-1 & CD44 
(Figure-4) as well as MKLP-1 & K15 (Figure-5).  Of the cells photographed with the MKLP-1 
& CD44 co-stain, 16% of the treated cells and 2.7% of the untreated cells stained positive for 
CD44.  For one midbody, 2.6% of the treated cells and 1.8% of the untreated cells stained 
positive.  Only 0.3% of the treated cells and about 0.05% of the untreated cells stained positive 
for greater than on midbody. 
MDA231 Dox+ MKLP-1 & CD44 MDA231 Dox- MKLP-1 & CD44 
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 Figure 4: Photos of PC3 Cells.  Cells were either treated (left panel) or untreated (right panel) with Dox, 
then stained for MKLP-1 & CD44.  Shown at  20x. 
 
For the MKLP-1 & K15 co-stain, close to 12% of the treated cells and about 2.8% of the 
untreated cells stained positive for K15.  For the midbody staining, 2% of the treated cells stained 
positive for one midbody, and none stained positive for more than one midbody. For the untreated 
cells, however, about 4% were positive for one midbody, and 0.2% for more than one midbody. 
Figure 5: Photos of PC3 Cells.  Cells were either treated (left panel) or untreated (right panel) with Dox, 
then stained for MKLP-1 & K15.  Shown at 20x.  
 
 In the NPrEC cell experiment stained for MKLP-1 & K15 (Figure-6), about 19.2% of the 
treated cells stained positive for K15, whereas only 3.8% of the untreated cells were positive for 
K15.  For the midbody staining, the treated cells showed about 6% positive for one midbody and 
PC3 Dox+ MKLP-1 & K15 PC3 Dox- MKLP-1 & K15 
PC3 Dox- MKLP-1 & CD44 PC3 Dox+ MKLP-1 & CD44 
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0.8% for more than one midbody.  For the untreated cells, 16% stained positive for one midbody, 
and 4% for more than one midbody. 
 
 Figure 6:  Photos of NPrEC Cells.  Cells were treated (left panel) or untreated (right panel) with Dox, 
then stained for MKLP-1 & K15.  Shown at 20X magnification. 
 
 For the NPrEC cells stained for MKLP-1 and CD44 (Figure-7), about 1.8% of the 
untreated and about 53% of the treated cells positively stained for CD44.  For the MKLP-1 
staining, 11.7% of the untreated cells and about 5% of the treated cells showed one midbody.  For 
more than one midbody, 6.3% of the untreated cells, and 0.14% of the treated cells tested 
positive.  
 
Figure 7: Photos of NPrEC Cells.  Cells were treated (left panel) or untreated (right panel) with Dox, then 
stained for MKLP-1 & CD44.  Shown at 20x. 
NPrEC Dox- MKLP-1 & CD44 NPrEC Dox+ MKLP-1 & CD44 
NPrEC Dox- MKLP-1 & K15 NPrEC Dox+ MKLP-1 & K15 
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 The SEBE6E7 stains (Figure-8) were photographed separately (shown below).  For the 
K15 staining (lower row), 98.96% of the treated cells and 13% of the untreated cells stained 
positive for the CSC marker. The MKLP-1 midbody stain (upper row) results are as follows: 
0.76% treated and 3.17% untreated cells positive for one midbody, 1.7% and 0% treated and 
untreated, respectively, positive for more than one midbody. 
 
Figure 8: Photos of SEBE6E7 treated and untreated cells with stem cell markers K15 and MKLP-1.  
 
 Tumor 1C cells (Figure 9) were stained with MKLP-1 & K15.  About 1.15% of the 
untreated cells and 10% of the Dox treated cells stained positive for K15. As for MKLP-1, 10% 
of the untreated and 15.4% of the Dox treated cells stained positive for one midbody; 1.16% of 
the untreated and 0.71% of the Dox treated cells stained positive for more than one midbody. 
SEBE6E7 Dox+ & K15 SEBE6E7 Dox- & K15 
SEBE6E7 Dox+  MKLP-1 SEBE6E7 Dox- & MKLP-1 
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Figure 9: Photos of Tumor 1C Cells.  Cells were treated (left panel) or untreated (right panel) with Dox, 
then stained for MKLP-1 and K15. 
 
No data was acquired for the Clone J cell line (Figure-10) due to the aforementioned 
problems we encountered with the cell line.  One photograph of the cell line was taken, however, 
and it is shown below. 
 
Figure 10: Photo of  Clone J Cells.  Untreated cells were  
stained for MKLP-1 and K15.  Shown at 20x. 
 
 As with the Clone J cell line, no quantitative data was collected for the HCT116-/- cell 
line (Figure-11).  The photos taken of the cell line are shown below. 
 
Clone J Dox- MKLP-1 & K15 
Tumor 1C Dox+ MKLP-1 & K15 Tumor 1C Dox- MKLP-1 & K15 
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Figure 11: Photos of HCT116 -/- Cells.  Treated (left panel) and untreated (right panel) cells were stained 
for MKLP-1 and CD133.  Cells shown at 20x. 
 
 
Statistical Analysis 
 
 In order to analyze the results obtained from the counting of the merged images of 
each stained slide, a student t-test was used with a 5% significance level.  A one tailed P-
value was used to determine statistical significance because it was determined that the 
data was one directional, in that the positive staining for stem cell markers could only 
increase above zero, and not go below zero. 
 First, the staining of stem cell markers was compared between the doxorubicin 
treated and the untreated control cells.  For each cell line, it was found that at least one 
stem cell marker was significantly different between treated and untreated cells of the 
same type.  The results of the t-test for treated vs. untreated cells are shown in Table 7 
below.  The mean values of percent positive staining for each stem cell marker in each 
cell line are also shown in Table 8.   
 
HCT116 -/- Dox- MKLP-1 & 
CD133 
HCT116 -/- Dox+ MKLP-1 & 
CD133 
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Cell Line Stem Cell Marker P-Values (One 
Tailed T-Test) 
Significance 
(α=.05) 
MDA231 CD44 0.000 Y 
MKLP-1 (1 midbody) 0.018 Y 
MKLP-1 (>1 midbody) No P-Value Inconclusive 
PC3 (CD44 + 
MKLP1 costain) 
CD44 0.142 N 
MKLP1 (1 midbody) 0.297 N 
MKLP1 (>1 midbody) 0.218 N 
PC3 (K15 + 
MKLP1 costain) 
K15 0.042 Y 
MKLP1(1 midbody) 0.091 N 
MKLP1 (>1 midbody) 0.089 N 
NPrEC (CD44 + 
MKLP1 costain) 
CD44 0.003 Y 
MKLP1 (1 midbody) 0.030 Y 
MKLP1 (>1 midbody) 0.012 Y 
NPrEC (K15 + 
MKLP1 costain) 
K15 0.053 N 
MKLP1(1 midbody) 0.044 Y 
MKLP1 (>1 midbody) 0.060 N 
SebE6E7 K15 0.000 Y 
MKLP1 (1 midbody) 0.016 Y 
MKLP1 (>1 midbody) 0.120 N 
Tumor 1C K15 0.005 Y 
MKLP1 (1 midbody) 0.195 N 
MKLP1 (>1 midbody) 0.297 N 
 
Table 7: Statistical Significance for Cell Line Staining.  Table shows comparison of Dox treated cells to 
untreated control cells (Y=significant, N=not significant). 
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  Mean % Positive 
Cell Line Stem Cell Marker Treated Untreated 
MDA231 CD44 95.238 4.445 
MKLP-1 (1 midbody) 18.254 2.930 
MKLP-1 (>1 midbody) 0.000 0.000 
PC3 (CD44 + MKLP1 
costain) 
CD44 16.065 2.693 
MKLP1 (1 midbody) 2.607 1.790 
MKLP1 (>1 midbody) 0.333 0.048 
PC3 (K15 + MKLP1 
costain) 
K15 11.976 2.785 
MKLP1(1 midbody) 2.189 3.910 
MKLP1 (>1 midbody) 0.000 0.203 
NPrEC (CD44 + MKLP1 
costain) 
CD44 1.790 52.873 
MKLP1 (1 midbody) 4.954 11.727 
MKLP1 (>1 midbody) 0.142 6.342 
NPrEC (K15 + MKLP1 
costain) 
K15 19.287 3.800 
MKLP1(1 midbody) 5.904 16.162 
MKLP1 (>1 midbody) 0.794 4.128 
SebE6E7 K15 98.965 13.001 
MKLP1 (1 midbody) 0.760 3.170 
MKLP1 (>1 midbody) 1.732 0.000 
Tumor 1C K15 10.004 0.147 
MKLP1 (1 midbody) 15.437 10.027 
MKLP1 (>1 midbody) 0.714 1.166 
 
Table 8: Mean Percentages of Cells Staining Positive for a Particular Stem Cell Marker. 
 
 Figures 12 and 13 contain the mean amounts of positive staining for the observed 
stem cell markers in graphical form.  Figure 12 shows percent positive staining for cells 
treated with Doxorubicin, while Figure 13 shows positive staining of untreated cells.  It is 
clear from the graphs that there was significantly more staining for most of the stem cell 
markers in almost all cell lines treated with doxorubicin compared to the control cells.  
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Figure 12: Bar Graph Analysis of the Mean % Positive Staining for Particular Stem Cell Markers in 
Cell Lines Treated with Doxorubicin. 
 
 
Figure 13: Bar Graph Analysis of the Mean % Positive Staining for Particular Stem Cell Markers in 
Control Cell Lines (untreated). 
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After the results of the treated and untreated cells were compared, the difference 
in stem cell marker staining was compared in tumor versus normal tissue.  Table 9 shows 
the statistical significance of the normal vs. tumoric tissue comparison for each cell line 
tested, both treated and untreated.  There was a statistically significant difference in stem 
cell marker staining in normal vs. tumoric tissue in at least one stem cell marker for each 
tissue type compared, for both Dox treated and control cells. 
  P-Values                             
(one tailed T-test) 
Statistical Significance 
(α=0.05) 
 
 Treated Untreated Treated Untreated 
NPrEC vs. PC3 
(CD44, MKLP1 
costain) 
CD44 0.019 0.330 Y N 
MKLP1 (1 midbody) 0.095 0.007 N Y 
MKLP1 (>1 
midbody) 
0.307 0.011 N Y 
NPrEC vs. PC3 
(K15, MKLP1 
costain) 
K15 0.220 0.381 N N 
MKLP1 (1 midbody) 0.023 0.027 Y Y 
MKLP1 (>1 
midbody) 
0.178 0.035 N Y 
SebE5E7 vs. 
Tumor 1C (K15, 
MKLP1) 
K15 0.000 0.029 Y Y 
MKLP1 (1 midbody) 0.014 0.011 Y Y 
MKLP1 (>1 
midbody) 
0.256 0.016 N Y 
 
Table 9: Statistical Significance in Stem Cell Marker Staining Between Normal Cell Lines and 
Tumor Cell Lines (Y=significant, N=not significant). 
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 Last, the percentage of cells containing either one or greater than one midbody 
was analyzed in each of the cell lines tested.  The results of this analysis are shown in 
Figure 14.  In Dox treated cells, midbodies were present in all cell lines tested, and 
multiple midbodies in all cell lines except for MDA231 cells.  In untreated control cells, 
there were midbodies present in all cell lines, and greater than one midbody in PC3, 
NPrEC, and Tumor 1C cells. 
 
Figure 14: The Mean Percentage of Cells Containing One Midbody and Greater Than 1 Midbody for 
Dox+ and Dox- Cells. 
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DISCUSSION 
 
Main Conclusions 
 
 The data collected from this project support the hypothesis that cancer stem cells 
remain in tumor cell populations after Dox chemotherapy.  In the comparison between 
Dox treated and untreated control cells, it was shown that there was a higher mean 
percentage of staining in Dox treated cell lines for cell lines MDA231, PC3, NPrEC, 
SebE6E7, and Tumor 1C, for at least one stem cell marker tested.  There was 
significantly different staining between Dox-treated and untreated cells for CD44 and 
MKLP-1 in MDA231, K15 in PC3, CD44 and MKLP-1 in NPrEC, K15 and MKLP-1 in 
SebE6E7, and K15 in Tumor 1C.  This information supports the hypothesis that a 
population of stem cells remain after Dox treatment in the cell lines tested. 
 The presence of stem cell markers was also compared between normal tissue and 
tumor tissue of the same type.  This analysis shows a significant difference in staining 
between normal and tumoric cells in all Dox-treated cell lines for at least one stem cell 
marker.  When comparing tumoric PC3 cells to normal NPrEC cells, there was a 
significant difference in CD44 and MKLP-1 staining.  For normal SebE6E7 and tumoric 
Tumor 1C cells, there was a significant difference in K15 and MKLP-1 staining.  In the 
comparison of normal vs. tumor cell lines however, statistical significance was achieved 
more often in untreated than in Dox treated experiments. 
 MKLP-1 staining for midbodies was also examined among the cell lines tested.  
The percentage of cells in each experiment with one midbody and the percentage with 
greater than one midbody were analyzed.  The results show that there is a higher 
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percentage of staining for one midbody in Dox treated than in untreated cells in 
MDA231, SebE6E7, and Tumor 1C.  However, there was a decrease in midbody staining 
in untreated cells for the PC3 and NPrEC lines.  In examining the percentages of cells 
containing more than one midbody, treated MDA231 and PC3 lines had more cells with 
multiple midbodies than untreated of the same type.  In NPrEC and Tumor 1C however, 
there was a larger percentage of cells with multiple midbodies in untreated cells than in 
Dox treated.  In MDA231 there were no cells with more than one midbody.   
 
Significance 
 
 Many of the results obtained from these experiments are in accordance with the 
Cancer Stem Cell theory discussed in the Background section.  Dalerba et al (2007) 
proposed that tumors are comprised of a heterogeneous mixture of cells, which was 
supported by our experiments with Doxorubicin.  The treatment of cell lines with 
doxorubicin demonstrated that there was a mixture of differentiated cells, which were 
killed by the Dox chemotherapy drug, and cancer stem cells, which were left behind after 
chemotherapy and stained positive for the various stem cell markers in the 
immunofluorescence experiments.  Cho, Clarke, and Dalerba also explained several 
characteristics of CSC populations; one being that tumorigenic CSCs contain surface 
markers such as cell determinants (CD’s), and another that cells transplanted into mice 
regenerate a new tumor with a mixed population of cells that is the same as the parent 
tumor.  In our experiments, both CD44 and CD133 were identified in CSC populations 
remaining after chemotherapy treatment.    
 44
 Current research by Lyle, Doxsey, and Houghton (unpublished) indicates that 
midbodies may be retained in stem cells, but are degraded in differentiated cells.  The 
data gathered from our immunofluorescence experiments indicates a significant amount 
of midbodies retained in the stem cell population left over after Dox treatment in several 
cell lines.  Also several cells contained multiple midbodies, further supporting the theory 
that stem cells retain midbodies after cell division.   
 
Complications with Experimentation 
 
 Due to the fact that the MQP takes place over a short period of time, most of the 
problems encountered during experimentation would have been solved if more time had 
been available.  Unfortunately additional time was not a possibility, so many of the 
experiments were not able to be perfected.   There were several complications that arose 
during the culturing of cell lines used for experimentation.  At some times the wrong 
culture media were used, or different formulas of culture media needed to be created for 
the cells to be able to grow better.  Cells sometimes failed to grow for unknown reasons.  
In several instances, we were not aware of the passage limit for some cell lines, and we 
attempted to passage them beyond their capacity.  When plating cells with coverslips for 
treatment, plastic coverslips were mistakenly sometimes used in place of glass coverslips, 
which resulted in ruining the slips after fixing with acetone.  In addition, drug 
administration sometimes did not go smoothly, in that it took longer than expected for 
cells to die after Dox was administered, or the wrong concentration of drug was used for 
the experiment. 
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 There were also several problems that arose during immunofluorescent staining.  
In several instances, the wrong antibody was used to stain cells, such as using the same 
species of antibody to stain two different markers, so that they would not be 
distinguishable from one another.  At times there was also overexposure of cells to dye, 
or the wrong concentration of antibody stain was used.  In some cases, the reason that a 
stain failed to work was unknown.  This resulted in the necessity of repeating the 
immunofluorescent dying process several times for some cell lines. 
 Lastly, there were some complications with fluorescent microscopy.  At times 
there were not enough cells left on the slides after Dox treatment, which caused us to 
have to repeat some of the treatment experiments.  Many of the slides that we looked at 
were too blurry to be used for counting; this could have been due to a dirty lens, dead 
cells on the coverslips, cells on both sides of the coverslip, or over-confluence of cells.  
In addition, it was difficult to judge how many photos should be taken of each slide to 
obtain a number of cells sufficient for statistical analysis.  Therefore, some of the 
statistical data that was collected may not be sufficiently accurate because of a small 
sample size.   
 
Future Experiments 
  
 Due to the time constraints of the MQP, it was not possible to perform all of the 
experiments that would have provided useful data for this project.  Experimentation on 
four of the cell lines that were originally intended could not be completed: Clone A, 
Clone J, HCT116+/+, and HCT116-/- cells.  In order to better characterize the CSCs 
associated with these important tumor cell lines, more chemotherapy and 
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immunofluorescence experiments should be done.  In addition, not all of the cell lines 
showed data that was statistically significant for the stem cell markers tested.  These 
experiments should be re-done to obtain more significant data. 
 The experiments in this MQP only tested for a small variety of stem cell markers 
known to exist in the tissue types that were tested.  Future experiments may aim to 
further characterize CSCs by staining for different stem cell markers that could also be 
present in these tissue types.  In addition, cell lines of other tissue types, such as brain 
tumor lines, could be tested to gain more information about a broader spectrum of 
diseases in which CSCs may play a role.   
 One last experiment that may prove to be interesting would be implantation of 
cancer stem cells isolated by chemotherapy treatment into mice to determine whether or 
not the CSCs have the ability to regenerate a tumor in vivo that is similar to the original 
parent tumor.  Other research has demonstrated success in regenerating tumors in mice 
after implanting cells that remained after chemotherapy treatment (Levina et al; Gu et al., 
2007; Dalerba et al., 2007; Ricci-Vitiani et al, Raouf et al., 2005; and Kang & Kang).   
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APPENDIX A: Table of Cell Counts 
 
Cell Line Merge # 
Total # 
Cells 
# Cells Pos 
K15 or CD44 
% Pos K15 or 
CD44 
# Cells Pos 
MKLP-1 (1 
midbody) 
% Pos MKLP-1 
(1 midbody) 
# Cells Pos 
MKLP-1 (>1 
Midbody) 
% Pos MKLP-1 
(>1 midbody) 
MDA231 Treated 
(CD44/MKLP-1) 
1 7 7 100 1 14.28571429 0 0 
2 7 5 71.42857143 1 14.28571429 0 0 
3 4 4 100 0 0 0 0 
4 6 6 100 2 33.33333333 0 0 
5 7 7 100 1 14.28571429 0 0 
6 6 6 100 2 33.33333333 0 0 
Total Cells 37 Mean % Pos 95.23809524 Mean % Pos 18.25396825 Mean % Pos 0 
MDA231 
Untreated 
(CD44/MKLP-1) 
1 40 2 5 0 0 0 0 
2 75 2 2.666666667 0 0 0 0 
3 147 4 2.721088435 6 4.081632653 0 0 
4 89 5 5.617977528 3 3.370786517 0 0 
5 67 0 0 5 7.462686567 0 0 
6 75 8 10.66666667 2 2.666666667 0 0 
Total Cells 493 Mean % Pos 17.41578493 Mean % Pos 5.119391523 Mean % Pos 0 
PC3 Treated 
(K15/MKLP-1) 
1 59 4 6.779661017 1 1.694915254 0 0 
2 83 1 1.204819277 0 0 0 0 
3 89 28 31.46067416 4 4.494382022 0 0 
4 62 4 6.451612903 1 1.612903226 0 0 
5 101 11 10.89108911 4 3.96039604 0 0 
6 73 11 15.06849315 1 1.369863014 0 0 
Total Cells 467 Mean % Pos 12.75316208 Mean % Pos 2.607407297 Mean % Pos 0 
PC3 Untreated 1 184 13 7.065217391 9 4.891304348 1 0.543478261 
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(K15/MKLP-1) 
2 88 1 1.136363636 0 0 0 0 
3 287 4 1.393728223 18 6.271777003 0 0 
4 148 6 4.054054054 9 6.081081081 1 0.675675676 
5 215 1 0.465116279 7 3.255813953 0 0 
6 270 7 2.592592593 8 2.962962963 0 0 
Total Cells 1192 Mean % Pos 4.208604894 Mean % Pos 3.724335235 Mean % Pos 0.174164848 
PC3 Treated 
(CD44/MKLP-1) 
1 50 35 70 3 6 1 2 
2 66 4 6.060606061 0 0 0 0 
3 48 7 14.58333333 3 6.25 0 0 
4 74 3 4.054054054 0 0 0 0 
5 59 1 1.694915254 2 3.389830508 0 0 
6 63 0 0 0 0 0 0 
Total Cells 360 Mean % Pos 14.3716448 Mean % Pos 2.766309392 Mean % Pos 0.310594978 
PC3 Untreated 
(CD44/MKLP-1) 
1 91 0 0 0 0 0 0 
2 99 4 4.04040404 3 3.03030303 0 0 
3 199 1 0.502512563 0 0 0 0 
4 170 0 0 10 5.882352941 0 0 
5 192 25 13.02083333 0 0 0 0 
6 155 2 1.290322581 3 1.935483871 0 0 
7 297 0 0 5 1.683501684 1 0.336700337 
Total Cells 1203 Mean % Pos 2.693438931 Mean % Pos 1.790234504 Mean % Pos 0.048100048 
NPrEC Treated 
(K15/MKLP-1) 
1 19 2 10.52631579 2 10.52631579 0 0 
2 18 11 61.11111111 2 11.11111111 1 5.555555556 
3 22 7 31.81818182 1 4.545454545 0 0 
4 12 0 0 0 0 0 0 
5 25 1 4 1 4 0 0 
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6 17 2 11.76470588 1 5.882352941 0 0 
7 19 3 15.78947368 1 5.263157895 0 0 
Total Cells 132 Mean % Pos 19.28711261 Mean % Pos 5.90405604 Mean % Pos 0.793650794 
NPrEC Untreated 
(K15/MKLP-1) 
1 37 7 18.91891892 8 21.62162162 2 5.405405405 
2 27 0 0 2 7.407407407 0 0 
3 103 2 1.941747573 14 13.59223301 4 3.883495146 
4 103 2 1.941747573 9 8.737864078 2 1.941747573 
5 113 0 0 9 7.96460177 2 1.769911504 
6 85 0 0 32 37.64705882 10 11.76470588 
Total Cells 468 Mean % Pos 6.012789525 Mean % Pos 14.69640611 Mean % Pos 3.651273758 
NPrEC Treated 
(CD44/MKLP-1) 
1 69 41 59.42028986 7 10.14492754 0 0 
2 61 38 62.29508197 3 4.918032787 0 0 
3 78 11 14.1025641 3 3.846153846 0 0 
4 65 43 66.15384615 2 3.076923077 0 0 
5 117 34 29.05982906 3 2.564102564 1 0.854700855 
6 58 50 86.20689655 3 5.172413793 0 0 
Total Cells 448 Mean % Pos 46.17875675 Mean % Pos 6.345565673 Mean % Pos 0.643710659 
NPrEC Untreated 
(CD44/MKLP-1) 
1 30 1 3.333333333 7 23.33333333 2 6.666666667 
2 27 1 3.703703704 2 7.407407407 2 7.407407407 
3 27 1 3.703703704 1 3.703703704 2 7.407407407 
4 29 0 0 4 13.79310345 0 0 
5 29 0 0 4 13.79310345 4 13.79310345 
6 36 0 0 3 8.333333333 1 2.777777778 
Total Cells 178 Mean % Pos 8.131356784 Mean % Pos 10.95850719 Mean % Pos 5.528010481 
SebE6E7 Treated  
(K15) 
1 21 20 95.23809524         
2 39 39 100         
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3 39 39 100         
4 34 34 100         
5 43 43 100         
6 69 68 98.55072464         
Total Cells 245 Mean % Pos 85.98859667         
SebE6E7 
Untreated  (K15) 
1 100 3 3         
2 145 39 26.89655172         
3 119 38 31.93277311         
4 79 6 7.594936709         
5 98 5 5.102040816         
6 115 4 3.47826087         
Total Cells 656 Mean % Pos 23.42759427         
SebE6E7 Treated  
(MKLP-1) 
1 54   95.23809524 0 0 0 0 
2 30   4.445399883 1 0.333333333 0 0 
3 38   11.97605827 8 2.105263158 3 7.894736842 
4 8   2.693438931 0 0 0 0 
5 40     5 1.25 1 2.5 
6 46     4 0.869565217 0 0 
Total Cells 216 Mean % Pos 27.55611732 Mean % Pos 0.759693618 Mean % Pos 1.73245614 
SebE6E7 
Untreated  
(MKLP-1) 
1 22     1 4.545454545 0 0 
2 58     0 0 0 0 
3 106     6 5.660377358 0 0 
4 96     4 4.166666667 0 0 
5 96     2 2.083333333 0 0 
6 78     2 2.564102564 0 0 
Total Cells 456 Mean % Pos 27.55611732 Mean % Pos 2.825661155 Mean % Pos 0.247493734 
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Tumor 1C Treated 
(K15/MKLP-1) 
1 7 0 0 1 14.28571429 0 0 
2 5 1 0 3 60 0 0 
3 14 0 0 2 14.28571429 1 7.142857143 
4 11 2 0 2 18.18181818 0 0 
5 8 2 0 0 0 0 0 
6 8 1 0 2 25 0 0 
7 7 0 0 0 0 0 0 
8 12 2 0 1 8.333333333 0 0 
9 7 0 0 1 14.28571429 0 0 
10 13 1 0 0 0 0 0 
Total Cells 92 Mean % Pos 0 Mean % Pos 15.43722944 Mean % Pos 0.714285714 
Tumor 1C 
Untreated 
(K15/MKLP-1) 
1 31 0 0 0 0 0 0 
2 214 0 0 20 9.345794393 1 0.46728972 
3 97 1 1.030927835 9 9.278350515 3 3.092783505 
4 105 0 0 11 10.47619048 1 0.952380952 
5 177 0 0 16 9.039548023 4 2.259887006 
6 175 0 0 36 20.57142857 1 0.571428571 
7 122 0 0 14 11.47540984 1 0.819672131 
Total Cells 921 Mean % Pos 0.147275405 Mean % Pos 10.02667454 Mean % Pos 1.166205984 
 
  
 
 
